Evidence map›Paper›PMID 35748123›Full record

ArticleESC heart failure2022

Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real-world experience.

Thibaut Moulin, David Hamon, Kamila Djouadi, Thomas D'Humières, Nathalie Elbaz, Madjid Boukantar, Céline Zerbib, Ségolène Rouffiac, Tarvinder S Dhanjal, Laura Ernande and 4 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Thibaut MoulinDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
David HamonDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Kamila DjouadiDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Thomas D'HumièresDepartment of Physiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Nathalie ElbazDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Madjid BoukantarDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Céline ZerbibDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Ségolène RouffiacDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Tarvinder S DhanjalDepartment of Cardiac Electrophysiology, University of Warwick, Coventry, UK.
Laura ErnandeDepartment of Physiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Geneviève DerumeauxDepartment of Physiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Emmanuel TeigerDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Thibaud DamyDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Nicolas LelloucheDepartment of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Hôpitaux Universitaires Henri-Mondor · FRInserm · FRUniversity of Warwick · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study sought to describe and evaluate the impact of a routine in-hospital cardiac resynchronization therapy (CRT) programme, including comprehensive heart failure (HF) evaluation and systematic echo-guided CRT optimization. METHODS AND

resultsCRT implanted patients were referred for optimization programme at 3 to 12 months from implantation. The program included clinical and biological status, standardized screening for potential cause of CRT non-response and systematic echo-guided atrioventricular and interventricular delays (AVd and VVd) optimization. Initial CRT-response and improvement at 6 months post-optimization were assessed with a clinical composite score (CCS). Major HF events were tracked during 1 year after optimization. A total of 227 patients were referred for CRT optimization and enrolled (71 ± 11 years old, 77% male, LVEF 30.6 ± 7.9%), of whom 111 (48.9%) were classified as initial non-responders. Left ventricular lead dislodgement was noted in 4 patients (1.8%), and loss or ≤90% biventricular capture in 22 (9.7%), mostly due to arrhythmias. Of the 196 patients (86%) who could undergo echo-guided CRT optimization, 71 (36.2%) required VVd modification and 50/144 (34.7%) AVd modification. At 6 months post-optimization, 34.3% of the initial non-responders were improved according to the CCS, but neither AVd nor VVd echo-guided modification was significantly associated with CCS-improvement. After one-year follow-up, initial non-responders maintained a higher rate of major HF events than initial responders, with no significant difference between AVd/VVd modified or not.

conclusionsOur study supports the necessity of a close, comprehensive and multidisciplinary follow-up of CRT patients, without arguing for routine use of echo-guided CRT optimization.

Indexed as

Cardiac Resynchronization TherapyHeart FailureAgedAged, 80 and overCardiac Resynchronization Therapy DevicesEchocardiographyFemaleHumansMaleMiddle AgedTreatment OutcomeAtrioventricular delayCardiac resynchronization therapyEchocardiographyHeart failureInterventricular delayOptimization

Identifiers

PMID35748123
PMCPMC9715781
OpenAlexW4283371182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.